HK1123306A1 - Compositions and methods for cellular imaging and therapy - Google Patents

Compositions and methods for cellular imaging and therapy

Info

Publication number
HK1123306A1
HK1123306A1 HK09101029.4A HK09101029A HK1123306A1 HK 1123306 A1 HK1123306 A1 HK 1123306A1 HK 09101029 A HK09101029 A HK 09101029A HK 1123306 A1 HK1123306 A1 HK 1123306A1
Authority
HK
Hong Kong
Prior art keywords
therapy
compositions
methods
cellular imaging
cellular
Prior art date
Application number
HK09101029.4A
Other languages
English (en)
Chinese (zh)
Inventor
David J Yang
Chang Sok Oh
Dong-Fang Yu
Ali Azhdarinia
Saady Kohanim
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of HK1123306A1 publication Critical patent/HK1123306A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005Compounds without a metal-carbon linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0404Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0491Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0493Steroids, e.g. cholesterol, testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
HK09101029.4A 2006-04-19 2009-02-05 Compositions and methods for cellular imaging and therapy HK1123306A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74514806P 2006-04-19 2006-04-19
PCT/US2006/016784 WO2007120153A1 (en) 2006-04-19 2006-05-04 Compositions and methods for cellular imaging and therapy

Publications (1)

Publication Number Publication Date
HK1123306A1 true HK1123306A1 (en) 2009-06-12

Family

ID=38609808

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09101029.4A HK1123306A1 (en) 2006-04-19 2009-02-05 Compositions and methods for cellular imaging and therapy

Country Status (13)

Country Link
EP (1) EP2013221B1 (xx)
JP (1) JP2009534381A (xx)
KR (2) KR20090014164A (xx)
CN (1) CN101516899B (xx)
AU (1) AU2006342202C1 (xx)
BR (1) BRPI0621580B8 (xx)
CA (1) CA2649869C (xx)
DK (1) DK2013221T3 (xx)
ES (1) ES2544244T3 (xx)
HK (1) HK1123306A1 (xx)
IL (1) IL194826A (xx)
NO (1) NO341574B1 (xx)
WO (1) WO2007120153A1 (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
WO2008091530A2 (en) * 2007-01-19 2008-07-31 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
JPWO2015152128A1 (ja) * 2014-03-31 2017-04-13 長瀬産業株式会社 アミノ酸前駆体、アミノ酸およびその製造方法、ならびに該アミノ酸を用いたpet診断用トレーサー
GB201417067D0 (en) 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
AU2017368135A1 (en) * 2016-11-30 2019-06-13 Tyme, Inc. Tyrosine derivatives and compositions comprising them
KR20200031663A (ko) * 2017-07-18 2020-03-24 비리팜 엔터프라이즈 엘엘씨 칸나비노이드 유사체 공액체를 포함하는 조성물 및 사용 방법
US11090395B2 (en) * 2018-09-14 2021-08-17 SeeCure Taiwan Co., Ltd. Composition for cross talk between estrogen receptors and cannabinoid receptors
JP2022532210A (ja) 2019-05-14 2022-07-13 タイム,インコーポレーテッド がんを処置する組成物および方法
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
US11554184B2 (en) 2021-03-26 2023-01-17 Vyripharm Enterprises, Inc. Synthetic cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases
CN117088825A (zh) * 2023-10-12 2023-11-21 成都威斯津生物医药科技有限公司 一种可离子化脂质、含该可离子化脂质的药物组合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988496A (en) * 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5650133A (en) * 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
US5684149A (en) * 1993-01-22 1997-11-04 Research Foundation Of State University Of New York Metal complexes for promoting catalytic cleavage of RNA by transesterification
US6770261B2 (en) * 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
EP1140864A2 (en) * 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6673333B1 (en) * 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
JP2004509152A (ja) 2000-05-12 2004-03-25 ユニバーシティ ホスピタル 放射性金属標識分子のプロキレート剤
PL359292A1 (en) * 2000-09-29 2004-08-23 Anormed Inc. Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
US20050255038A1 (en) * 2002-04-12 2005-11-17 A And D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof
AU2003303714B2 (en) 2003-01-13 2009-02-19 Bracco Imaging S.P.A. Improved linkers for radiopharmaceutical compounds
US8147805B2 (en) * 2005-01-05 2012-04-03 The Board of Regents of The University of T exas System Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications

Also Published As

Publication number Publication date
AU2006342202A1 (en) 2007-10-25
KR20140099557A (ko) 2014-08-12
CA2649869A1 (en) 2007-10-25
CA2649869C (en) 2014-11-18
NO341574B1 (no) 2017-12-04
NO20084821L (no) 2009-01-16
AU2006342202C1 (en) 2013-09-26
JP2009534381A (ja) 2009-09-24
EP2013221A1 (en) 2009-01-14
ES2544244T3 (es) 2015-08-28
BRPI0621580A2 (pt) 2011-05-10
EP2013221B1 (en) 2015-06-24
BRPI0621580B1 (pt) 2021-05-11
KR20090014164A (ko) 2009-02-06
BRPI0621580B8 (pt) 2021-05-25
IL194826A0 (en) 2009-08-03
CN101516899A (zh) 2009-08-26
EP2013221A4 (en) 2010-12-15
AU2006342202B2 (en) 2013-03-07
CN101516899B (zh) 2016-07-06
KR101653182B1 (ko) 2016-09-01
WO2007120153A1 (en) 2007-10-25
IL194826A (en) 2013-08-29
DK2013221T3 (en) 2015-09-28

Similar Documents

Publication Publication Date Title
EP2146632A4 (en) COMPOSITIONS AND METHODS FOR CELLULAR IMAGE PRESENTATION AND THERAPY
IL257681A (en) Methods and compositions for the treatment of cancer
IL194826A0 (en) Compositions and methods for cellular imaging and therapy
HRP20160949T1 (hr) Novi sastavi i metode za liječenje karcinoma
EP1718282A4 (en) PROCESS AND COMPOSITIONS FOR IMAGE PRESENTATION
HK1137670A1 (en) Compositions and methods for arthrodetic procedures
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
HK1145339A1 (zh) 用於定向整合的方法和組合物
ZA200907492B (en) Compositions for targeted imaging and therapy
PL2066694T3 (pl) Kompozycje i sposoby diagnozowania i leczenia nowotworu
EP2032166A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER
IL191072A0 (en) Therapeutic compositions and methods
EP1848464A4 (en) COMPOSITIONS AND METHODS FOR MULTIMODAL IMAGING
GB0513812D0 (en) Compounds for imaging and therapy
EP2018163A4 (en) ILLUSTRATIVE APPARATUS AND METHOD
IL198723A0 (en) Methods and compositions for therapeutic treatment
EP2049151A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
IL196843A0 (en) Compositions and methods for the treatment of radiation proctosigmoitis
HK1129596A1 (en) Methods and compositions for treating disease
EP2099491A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER
GB0617299D0 (en) Compounds for imaging and therapy
GB0622341D0 (en) Novel compounds and methods for their preparation
GB0608960D0 (en) Imaging agent
GB0517546D0 (en) Therapeutic methods and compositions
PT3067054T (pt) Novas composições e métodos para o tratamento de cancro